非肌层浸润性膀胱癌围手术期膀胱灌注化疗的指南推荐应用差异及来源
该研究纳入2015-2017年北加州整合医疗系统988例非肌层浸润性膀胱癌患者,分析膀胱灌注化疗(IVC)按疾病风险的使用情况,并评估低-中危患者中多层面因素对IVC使用差异的贡献。结果显示低-中危和高危患者接受IVC比例相似(36% vs 34%),服务区域量及提供者/服务区域层面因素解释了大量IVC使用差异。
要点
- 低-中危和高危非肌层浸润性膀胱癌患者接受IVC比例相似(36% vs 34%)。
- 服务区域量与IVC使用强相关,高量vs低量校正OR为0.08(95%CI 0.01-0.58)。
核心结论
- 研究结果提示改善IVC规范使用存在机会,未来需评估低-中危患者中提供者和实践层面的障碍。
研究设计与样本
- 回顾性队列研究,纳入2015-2017年北加州整合医疗系统988例非肌层浸润性膀胱癌患者。
- 采用随机截距logistic回归模型评估多层面因素与IVC使用的关系,并计算组内相关系数。
主要发现
- 低-中危和高危患者接受IVC比例相似(36% vs 34%)。
- 服务区域量与IVC使用强且统计学显著相关,高量vs低量校正OR为0.08(95%CI 0.01-0.58)。
临床怎么用
- 临床应关注低-中危非肌层浸润性膀胱癌患者IVC的规范使用,并识别提供者及实践层面的障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine intravesical chemotherapy (IVC) use according to non-muscle-invasive bladder cancer patient disease risk, and the contributions of multilevel factors to variation in proficient use among patients with low-intermediate disease. METHODS: This study included 988 patients diagnosed with non-muscle-invasive bladder cancer in an integrated health system in Northern California from 2015-2017. We calculated IVC receipt by disease risk, and among patients with low-intermediate risk disease, assessed the relationship between multilevel factors and IVC receipt using a logistic regression model with random intercepts for provider and service area, and patient-, provider-, and service area-level fixed effects. We further assessed the association of provider- and service area-level factors with IVC use by examining intraclass correlation coefficients. RESULTS: Similar proportions of low-intermediate (36%) and high-risk (34%) patients received IVC. In the multivariate analysis, including low-intermediate risk patients, service area volume was strongly and statistically significantly associated with IVC use (adjusted odds ratio, high- vs low-volume: 0.08, 95% Confidence Interval: 0.01-0.58). Provider- and service area-level intraclass correlation coefficients were large, (38%, P = .0009 and 39% P = .03, respectively) indicating that much of the variance in IVC use was explained by factors at these levels. CONCLUSION: Our findings highlight opportunities to improve proficient use of IVC. Future research should assess provider- and practice-level barriers to IVC use among low-intermediate risk patients.
引用
- Check DK, Aaronson DS, Nielsen ME, et al. Perioperative Intravesical Chemotherapy for Patients WithNon-Muscle-invasive Bladder Cancer: Understanding the Extent of and Sources of Variation in Guideline-recommended Use. Urology. 2018. PMID: 30359712. doi:10.1016/j.urology.2018.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。